Thr491
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr491  -  p63 (human)

Site Information
PQQRNALtPTTIPDG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4668106

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 3 ) , mutation of modification site ( 1 , 2 , 3 ) , phospho-antibody ( 3 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
bone cancer ( 1 , 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , cancer, squamous cell carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CDK2 (human) ( 3 ) , HIPK2 (human) ( 1 )
Kinases, in vitro:
CDK2 (human) ( 3 ) , HIPK2 (human) ( 1 )
Treatments:
cisplatin ( 3 ) , seliciclib ( 3 )

Downstream Regulation
Effects of modification on p63:
protein degradation ( 1 , 2 , 3 )
Effects of modification on biological processes:
apoptosis, induced ( 1 ) , DNA repair, induced ( 1 ) , transcription, inhibited ( 1 )

References 

1

Lazzari C, et al. (2011) HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene 30, 4802-13
21602882   Curated Info

2

Di Costanzo A, et al. (2009) Homeodomain protein Dlx3 induces phosphorylation-dependent p63 degradation. Cell Cycle 8, 1185-95
19282665   Curated Info

3

Huang Y, et al. (2008) ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 7, 2846-55
18769144   Curated Info